Overview

To Investigate the Efficacy of Treatment With Oral NA-921 (Bionetide) Versus Placebo in Females With Rett Syndrome

Status:
RECRUITING
Trial end date:
2026-11-30
Target enrollment:
Participant gender:
Summary
Primary Objective To investigate the efficacy of treatment with oral Bionetide versus placebo in girls and women with Rett syndrome Key Secondary Objective To investigate the efficacy of treatment with oral Bionetide versus placebo on ability to communicate in girls and women with Rett syndrome
Phase:
PHASE3
Details
Lead Sponsor:
Biomed Industries, Inc.